$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How long can one live with non-small cell lung cancer treated with adagrasib
2025-10-19 11:44:20
Check Details
How long can you live if you take Platinib in the late stage of lung cancer
2025-10-19 11:44:20
Check Details
How effective is entrectinib in treating brain metastases from lung cancer
2025-10-19 11:44:20
Check Details
What is the difference between erlotinib and gefitinib?
2025-10-19 11:44:20
Check Details
How long can one live after gefitinib is used to treat advanced lung cancer?
2025-10-19 11:44:20
Check Details
What is the target of ceritinib?
2025-10-19 11:44:20
Check Details
What is the effect of AMG510 on non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
Which generation of targeted drug is cabozantinib?
2025-10-19 11:44:20
Check Details
What is the objective response rate of TAK-788 in treating lung cancer?
2025-10-19 11:44:20
Check Details
Is it okay to take poziotinib after becoming resistant to osimertinib?
2025-10-19 11:44:20
Check Details
Which of the fourth generation lung cancer targeted drugs, Amivantamab or Mobocertinib, is more effective?
2025-10-19 11:44:20
Check Details
What is the efficacy of Amivantamab combined with Lazertinib?
2025-10-19 11:44:20
Check Details
1
2
...
4122
4123
4124
4125
4126
4127
4128
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
2
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
3
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
4
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
5
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
6
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
7
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
8
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
9
Vemurafenib (Zelboraf) Complete Medication Guide
10
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
11
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
12
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options